Joint Formulary & PAD

Spacer / holding chamber device with mask - Asthma

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Spacer device
Associated Icons :
Restrictions / Comments :
Important

AeroChamber Plus Flow-Vu Anti-Static with adult large mask - from 13 years

AeroChamber Plus Flow-Vu Anti-Static with adult small mask - from 13 years

 

Status 2

Green
Formulations :
  • Spacer device
Associated Icons :
Restrictions / Comments :
Important

AeroChamber Plus Flow-Vu Anti-Static with medium mask child 1-5 years - From 1 to 5 years

 

Status 3

Green
Formulations :
  • Spacer device
Associated Icons :
Restrictions / Comments :
Important

AeroChamber Plus Flow-Vu Anti-Static with small mask infant 0-18 months - From 0 to 18 months

 

Status 4

Green
Formulations :
  • Spacer device
Associated Icons :
Restrictions / Comments :
Important

Volumatic with paediatric mask - 4 years and under. Compatible with Clenil Modulite, Salamol and Seretide

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Spacer / holding chamber device with mask
Indication :
Asthma
Group Name :
Keywords :
Brand Names Include :
AeroChamber Plus Flow-Vu Anti-Static with adult large mask, AeroChamber Plus Flow-Vu Anti-Static with adult small mask, AeroChamber Plus Flow-Vu Anti-Static with medium mask child 1-5 years, AeroChamber Plus Flow-Vu Anti-Static with small mask infant 0-18 months, Volumatic with paediatric mask
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
4

Other Indications

Below are listed other indications that Spacer / holding chamber device with mask is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Asthma.

Committee Recommendations (1)

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.